<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="168215">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01971099</url>
  </required_header>
  <id_info>
    <org_study_id>TTM1</org_study_id>
    <nct_id>NCT01971099</nct_id>
  </id_info>
  <brief_title>Effects of Tribulus Terrestris in Women With Hypoactive Sexual Desire Disorder</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal University of Minas Gerais</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal University of Minas Gerais</source>
  <oversight_info>
    <authority>Brazil: National Committee of Ethics in Research</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypoactive Sexual Desire Disorder (HSDD) is the most prevalent female sexual dysfunction in
      society and is strongly linked to the quality of life of women. The androgen hormones
      decline over age in the premenopausal period, which occurs around 20 years. Tribulus
      terrestris is a plant native to India, recommended in the treatment of infertility, low
      libido and impotence. Its main active ingredient is the protodioscin, which has been
      attributed to an increase in testosterone levels and improved sexual function. The aim of
      this study is to evaluate the effects of Tribulus Terrestris in premenopausal women with
      HSDD.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Sexual Desire</measure>
    <time_frame>120 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>we will use the &quot;Quotient Sexual - Version Feminine (QS-F) brazilian questionary to make the evaluation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>serum levels of prolactin and thyroid-stimulating hormone (TSH)</measure>
    <time_frame>120 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>blood test</description>
  </secondary_outcome>
  <other_outcome>
    <measure>serum levels of testosterone and sex hormone-binding globulin (SHBG)</measure>
    <time_frame>120 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>blood test</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Hypoactive Sexual Desire Disfunction</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patients will use placebo for 120 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tribulus Terrestris</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients will use Tribulus terrestris (750 mg/day) during 120 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tribulus terrestris</intervention_name>
    <description>patients will use 750mg/day of tribulus terrestris</description>
    <arm_group_label>Tribulus Terrestris</arm_group_label>
    <other_name>tribulus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>patients will take one pill a day (the same shape of the drug)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  regular menstrual cycle

          -  with no  use of hormonal contraception within the last 3 months

          -  without any medication, drugs or alcohol.

          -  Healthy patients without systemic or psychiatric disease

        Exclusion Criteria:

          -  Patients with amenorrhea and/or pregnant.

               -  Patients who underwent bilateral oophorectomy.

               -  Patient smoker (10 cigarettes per day).

               -  Patients with blood pressure &gt; 160/90 mm ​​Hg.

               -  Patient with breast or endometrial carcinoma.

               -  Patients with a history of myocardial infarction.

               -  Patient with Diabetes.

               -  Patient with vaginal bleeding from any source.

               -  Patients with hepatic injury.

               -  Patients with active thrombophlebitis or thromboembolic disorders recent

               -  Patients with interpersonal relationship problems with your relationship or
                  partner

               -  Patients with sexual problems from your partner
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Selmo Geber, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal University of Minas Gerais</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Selmo Geber, MD PhD</last_name>
    <phone>55 31 34099304</phone>
    <email>sjgeber@terra.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fabiene Valle, MD</last_name>
    <phone>55 31 34099764</phone>
    <email>fabienebcv@yahoo.com.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital das Clinicas - Universidade Federal de Minas Gerais</name>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <zip>30130100</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Selmo Geber, MD PhD</last_name>
      <phone>55 31 34099304</phone>
      <email>sjgeber@terra.com.br</email>
    </contact>
    <contact_backup>
      <last_name>Fabiene Valle, MD</last_name>
      <phone>55 31 34099664</phone>
      <email>fabienebcv@yahoo.com.br</email>
    </contact_backup>
    <investigator>
      <last_name>Fabiene Vale, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 29, 2013</lastchanged_date>
  <firstreceived_date>October 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federal University of Minas Gerais</investigator_affiliation>
    <investigator_full_name>Selmo Geber</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>sexual function</keyword>
  <keyword>hypoactive</keyword>
  <keyword>desire</keyword>
  <keyword>androgens</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sexual Dysfunctions, Psychological</mesh_term>
    <mesh_term>Hypokinesia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
